Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol [ISRCTN62866759]

@article{Knaebel2005PhaseIT,
  title={Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol [ISRCTN62866759]},
  author={H P Knaebel and Angela M{\"a}rten and Jan Schmidt and Katrin Hoffmann and Christoph M. Seiler and Katja Lindel and Hubertus F. Schmitz-Winnenthal and Stefan Fritz and Thomas Herrmann and Hartmut Goldschmidt and Ulrich Mansmann and J{\"u}rgen Debus and Veronika Diehl and Markus W. B{\"u}chler},
  journal={BMC Cancer},
  year={2005},
  volume={5},
  pages={37 - 37}
}
After surgical intervention with curative intention in specialised centres the five-year survival of patients with carcinoma of the exocrine pancreas is only 15%. The ESPAC-1 trial showed an increased five-year survival of 21% achieved with adjuvant chemotherapy. Investigators from the Virginia Mason Clinic have reported a 5-year survival rate of 55% in a phase II trial evaluating adjuvant chemotherapy, immunotherapy and external-beam radiation. The CapRI study is an open, controlled… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…